We model 4Q:25 sales of $261.5 million, representing 8.9% year over year growth, reflecting expected increases across Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. We project adjusted EPS of $1.31 in 4Q:25 compared to adjusted EPS of $1.13 in 4Q:24, consistent with our sales assumptions and continued product adoption across the portfolio. Human Nutrition & Health remains the primary growth driver entering 4Q:25, supported by continued penetration of the specialty nutrient portfolio and sustained customer demand tied to high-protein, high-fiber, and lower-sugar formulations across food, beverage, and supplement applications. In Animal Nutrition & Health, our 4Q:25 expectations reflect continued adoption of rumen-protected encapsulated nutrients and a more constructive European competitive environment. Our Specialty Products assumptions incorporate improved market dynamics within performance gases and ongoing geographic expansion within plant nutrition, which helps mitigate historical U.S. seasonality. BCPC exits 2025 with a strong financial position, including low leverage and consistent free cash flow generation, supporting continued organic investment and disciplined capital allocation. Our 4Q:25 outlook reinforces our conviction in BCPC's consistent execution and durable demand profile, which remain central to the investment case. We maintain our $220 price target on BCPC shares, which is based on an intact 40× multiple to our 2026 adjusted EPS estimate of $5.50. Our moderate risk rating reflects BCPC's historical and projected earnings expansion, solid balance sheet, and strong free cash flow generation.